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Background Findings Findings (cont.) Discussion
The choice of neuromuscular blockade reversal agents impacts cost and 
operating room time.  Currently, the two medications used to reverse 
neuromuscular blockade are Neostigmine and Sugammadex. These 
medications differ in both cost and pharmacologic profiles which effect the 
time and predictability of reversal (Carron, Zarantonello, Tellaroli, & Ori, 
2016). Evaluating cost and time differences in reversal using Sugammadex 
and Neostigmine helps anesthesia providers select the appropriate 
medication. This evidence based practice project examined the difference in 
case length and operating room and reversal agent costs in cases using 
Sugammadex and Neostigmine at Providence Sacred Heart Medical Center. 
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Methods
• Retrospective, observational, evidence-based practice project
• Facility approved and IRB exemption determination granted
• Extracted case data deidentified and securely extracted into a HIPPA 
compliant REDCap database
• 11,944 cases evaluated from January 1, 2015 to December 31, 2018
• Inclusion criteria: ASA rating I, II, III; age <70; BMI <40; no diagnosed 
reduced pulmonary reserve conditions; no diagnosed pre-existing 
neuromuscular disease
• Cases removed: Surgical case duration not calculated; Neostigmine units 
<1 mg; Neostigmine units >5 mg; Sugammadex units >1000 mg; 
Sugammadex units <50 mg; Neither Neostigmine and Sugammadex used; 
Neostigmine and Sugammadex both used; Neostigmine given without 
Glycopyrrolate; Surgical procedures labeled ‘50’
• Analytical plan: Categorical variables described by frequency 
distributions; skewed continuous variables described by median and inter-
quartile range. Average medication costs, operating rooms minutes, and 
estimated operating room costs/case reported by reversal agent.
• Simulation: Total operating room and reversal agent costs were projected 
using an estimated operating room rate. Sensitivity analysis was completed 
in which the estimated operating room rate was varied. 
Operating room (OR) time and cost of neuromuscular blockade reversal 
agents were compared among cases in which either reversal agent could be 
used. The average reversal agent cost per case using Sugammadex was 
$99.13 compared to cases using Neostigmine/Glycopyrrolate at $32.55 per 
case.  A side by side comparison between Sugammadex and Neostigmine 
for like surgeries found that Sugammadex shortened surgical case duration 
for most procedures. Across all project cases the average surgical case 
duration for cases reversed using Sugammadex was 150 minutes (estimated 
operating room costs $14,623 per case). Neostigmine reversed cases 
averaged 153 minutes for surgical case duration (estimated operating 
rooms costs $14,901 per case). 
In simulated models, exclusive use of Sugammadex across all cases for the 
past four years would have resulted in cost savings across a range of 
estimated OR costs per minute. The findings of this observational project 
showed an average of about three minutes were saved in OR time when 
using Sugammadex versus Neostigmine. Surgical case duration is complex 
and multi-factorial. The results of this observational project signal a 
difference in OR time and agent costs as the result of reversal agent choice. 
Further randomized investigations are warranted. 
The choice of Sugammadex over Neostigmine as a neuromuscular blockade 
reversal agent resulted in lower operating room and reversal agent costs in 
simulated analyses in which the operating room cost per minute was varied. 
Average surgical duration (minutes) differed by choice of reversal agent 
used.  
Table 2: Neuromuscular Blockade Reversal Agent Cost Analysis (N=11,944) 
* Using Providence Sacred Heart Medical Center contracted medication prices 
** Total surgical case duration 










Neostigmine & Glycopyrrolate 
(n=4,745) 
Average Reversal Agent Medication 
Cost/Case* 
$99.13 $32.55 
Average Operating Room  
Minutes/Case** 
150 minutes 153 minutes 
Estimated Operating Room  
Cost/Case*** 
Projected Cost of Each Reversal Agent 








Table 1: Baseline Demographic and Clinical Characteristics (N=11,944) 
  n % 






ASA Rating I 1308 11% 
 II 7497 63% 
 III 3139 26% 
Kidney Disease  385 3% 
Smokers 









































Surgical Procedure in 2015  2679 22% 
Surgical Procedure in 2016  2846 24% 
Surgical Procedure in 2017 





  Median IQR 
Duration of Surgery (min)  126 92-175 
*Other procedures with <1% include: Interventional radiology, cardiothoracic, gastroenterology, dental, 




Table 3. Operating Room Cost Per Minute Sensitivity Analysis  
OR Cost/Min Sugammadex Neostigmine Amount Saved Using 
Sugammadex 
$30 $54,837,286 $55,314,321  $477,035  
$40 $72,721,696  $73,622,824  $901,128  
$50 $90,606,107  $91,931,327  $1,325,220  
$60 $108,490,517  $110,239,830  $1,749,313  
$70 $126,374,927  $128,548,334  $2,173,407  
$80 $144,259,338  $146,856,837  $2,597,499  
$90 $162,143,748  $165,165,340  $3,021,592  
$100 $180,028,159  $183,473,843  $3,445,684  
$110 $197,912,569  $201,782,347  $3,869,778  
* Cost if one reversal agent was used exclusively across all cases for the past four years. Cost savings 
generated using average total cost per case (case duration, operating room cost per minute and medication cost) 
 
